CEO, Pharmaceutical Services & Active Ingredients
Vice President and Head, API - Mature Markets
Vice President and Head, API - Emerging Markets
Dr. NM Sekhar, Vice President, API R&D
Executive VP & Global Head - Supply, Demand Planning & Delivery
Executive VP & Global Head - Supply, Demand Planning & Delivery
Vice President and Head, API Sales & Marketing, LATAM
Vice President, and Head – EU/CIS Market, API & B2B Collaborations
Vice President and Head, Strategic Projects API
Global Head of API Product Management & Head of Sales - US & Canada
Vice President, and Head, API - North Asia
Associate Vice President, API - BD & Portfolio
Associate Vice President, API Sales & Marketing, SEAMEA
Director, API - Sales & BD, Mexico & Canada
Rohit Jayant Dash, Director - API Sales & Marketing, GCC, Africa & Turkey
Ashish Rana, Director, API - BD & Sales, Europe
Director, API Sales & Marketing – LATAM
We specialise in manufacturing and supplying a wide range of APIs for generic formulation manufacturers in India and overseas. The company has a diversified portfolio of 150+ active pharmaceutical ingredients, which are used in major therapeutic areas such as gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Our API manufacturing facilities adhere to cGMP (ICH Q7) and are inspected on a regular basis by international regulatory bodies. We have eight commercially inspected USFDA production plants, six in India and one each in Mexico and the United Kingdom.
Dr. Reddy's API business operates in a number of global markets, including the United States of America, Latin America, Europe, India, Russia, and other CIS nations.
250+ APIs
8 Manufacturing sites
More than 1873 drug master files across global markets.
Over 325 ANDAs
More than 1000 patents field, and more than 70 own patents granted
Experience with complex APIs and formulations supporting early market entries.
Preferred pharma API supplier for pharma companies in more than 80 countries.
Our journey began with APIs in 1984, and we evolved from small molecules to large molecules and from APIs to finished formulations over the decades. Amidst this evolution, what has remained constant at the heart of our organization is a deep commitment to patients and the customers we serve through our core principles of collaboration and sustainability.
By the end of FY2024, we had served over 700 million patients and continue our endeavours to reach over 1.5 billion patients globally by 2030. This means almost one in every five people on this planet will use Dr. Reddy’s product or service. The health of people is strongly linked to the health of our planet. That's why our integrated report also shows how sustainability and business are strongly linked.
CPHI Milan is a global pharmaceutical event uniting the pharmaceutical community to advance human health. With a history spanning 35 years, the event has become a cornerstone for fostering connections and inspiring partnerships across the industry. CPHI Milan is a platform for professionals to engage with the latest innovations, share knowledge, and collaborate on projects that shape the future of pharmaceuticals.
Global Participation: The event expects to welcome 62,000 attendees and 2,400 exhibitors from 168+ countries, demonstrating its significant international reach.
Diverse Exhibition: Attendees can explore a wide range of products and services across various pharmaceutical sectors.
Networking Opportunities: CPHI Milan offers numerous opportunities for attendees to connect, build relationships, and forge partnerships.
Knowledge Exchange: The event features conferences, seminars, and workshops where industry experts share insights and discuss the latest trends.
Celebration of 35 Years: CPHI Milan 2024 marks a special milestone, celebrating 35 years of uniting the pharma community.
25/04/2024
USP recognized Dr. Reddy’s with a crystal award for significant contribution towards “New and modernized monograph submissions”
05/04/2024
Dr. Reddys Strategic collaboration with Industrial Promotion Services (IPS) to support the East African Combined Pharmaceutical Center (EACPC) in Kenya
05/12/2023
Dr. Reddy's Pioneers Pharma Advancements Through Strategic Partnerships and Innovation: A Glimpse into Vision 2030: Growth Trajectory and Opportunities for Indian Pharma
04/11/2022
Dr. Reddy’s API received the excellence in API – Technical Documentation award at Aché Laboratórios Parcerias para a Excelência (Partnerships – Excellence) event!
03/11/2021
Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2021
03/11/2021
Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2021
11/11/2021
The winner of the Corporate social responsibility (CSR) Initiative of the year at Global generics & Biosimilars Awards
19/10/2020
Dr. Reddy's recognized at the CPhI Pharma Awards 2020 as the winner in the category of ‘Excellence in Pharma: Sustainability’
本目錄中的任何信息(包括對任何產品或服務的任何引用)均不構成銷售要約,或被解釋為代表銷售要約。受有效專利保護的產品不提供或供應用於商業用途。但是,只要存在此類監管豁免,就可以出於監管提交的目的提供此類產品的研究數量。買方應對各自市場的專利方案進行獨立評估,並承擔所有與專利相關的責任。在印度受有效專利保護的產品不可用於商業用途,但可用於第 107A 節。